Literature DB >> 7923380

Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression.

R P de Groot1, L M Ballou, P Sassone-Corsi.   

Abstract

Activation of the adenylyl cyclase signaling pathway elicits the induction of genes via activators binding to cAMP-responsive elements (CREs). Nuclear factor CRE modulator (CREM) is activated by PKA-mediated phosphorylation on a serine at position 117. We show that Ser-117 is also phosphorylated by the mitogen-activated p70 S6 kinase (p70S6K) in vitro. Activation of cellular p70S6K by serum factors enhances Ser-117 phosphorylation and CREM transactivation. Coexpression of p70S6K significantly increases transactivation by a GAL4-CREM fusion. The macrolide rapamycin, a potent and specific inhibitor of p70S6K in vivo, completely blocks CREM activation induced by serum and by p70S6K. Thus, CREM constitutes a target for mitogenic signaling through p70S6K and may acts as a nuclear effector in which transduction pathways may converge and cross-talk.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923380     DOI: 10.1016/0092-8674(94)90402-2

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  43 in total

Review 1.  Mechanisms of transcriptional activation of cAMP-responsive element-binding protein CREB.

Authors:  P Haus-Seuffert; M Meisterernst
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

2.  Mitogenic signalling by delta opioid receptors expressed in rat-1 fibroblasts involves activation of the p70s6k/p85s6k S6 kinase.

Authors:  M A Wilson; A R Burt; G Milligan; N G Anderson
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

3.  Critical role of phosphoinositide 3-kinase cascade in adipogenesis of human mesenchymal stem cells.

Authors:  Weihua Yu; Zhenguang Chen; Jinli Zhang; Lirong Zhang; Hui Ke; Lihua Huang; Yanwen Peng; Xiuming Zhang; Shunong Li; Bruce T Lahn; Andy Peng Xiang
Journal:  Mol Cell Biochem       Date:  2007-12-02       Impact factor: 3.396

4.  Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sensitivity.

Authors:  H Kawasome; P Papst; S Webb; G M Keller; G L Johnson; E W Gelfand; N Terada
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

5.  Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells.

Authors:  Yan Liu; Shi-Yong Sun; Taofeek K Owonikoko; Gabriel L Sica; Walter J Curran; Fadlo R Khuri; Xingming Deng
Journal:  Mol Cancer Ther       Date:  2011-11-04       Impact factor: 6.261

6.  A phosphatidylinositol 3-kinase docking site in the cytoplasmic tail of the Jaagsiekte sheep retrovirus transmembrane protein is essential for envelope-induced transformation of NIH 3T3 cells.

Authors:  M Palmarini; N Maeda; C Murgia; C De-Fraja; A Hofacre; H Fan
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  A functional cyclic AMP response element plays a crucial role in neuroendocrine cell type-specific expression of the secretory granule protein chromogranin A.

Authors:  H Wu; S K Mahata; M Mahata; N J Webster; R J Parmer; D T O'Connor
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

8.  Regulation of mTOR and S6K1 activation by the nPKC isoforms, PKCepsilon and PKCdelta, in adult cardiac muscle cells.

Authors:  Phillip C Moschella; Vijay U Rao; Paul J McDermott; Dhandapani Kuppuswamy
Journal:  J Mol Cell Cardiol       Date:  2007-10-04       Impact factor: 5.000

9.  Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene.

Authors:  D De Cesare; S Jacquot; A Hanauer; P Sassone-Corsi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

10.  Constitutive activation of S6 kinase by deletion of amino-terminal autoinhibitory and rapamycin sensitivity domains.

Authors:  M Mahalingam; D J Templeton
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.